Genetic and Physical Characteristics of Rett Syndrome

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2014 by University of Alabama at Birmingham
Sponsor:
Collaborators:
Rare Diseases Clinical Research Network
University of Alabama at Birmingham
Greenwood Genetic Center
Baylor College of Medicine
Children's Hospital Boston
University of Rochester
Children's Hospital of Philadelphia
University of Colorado, Denver
Rush University Medical Center
Children's Hospital & Research Center Oakland
University of California, San Diego
Vanderbilt University
University of South Florida
Information provided by (Responsible Party):
Alan Percy, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00299312
First received: March 3, 2006
Last updated: December 11, 2014
Last verified: December 2014

March 3, 2006
December 11, 2014
March 2006
July 2019   (final data collection date for primary outcome measure)
Genetic and Physical Characteristics of Rett Syndrome [ Time Frame: July 31, 2019 ] [ Designated as safety issue: No ]
The primary endpoint is to determine the variables related to clinical outcome in terms of genotype and phenotype. The variables include growth, head circumference, stereotypic movements, periodic breathing, epilepsy, scoliosis, and longevity. Summative data are provided by the Clinical Severity Scale (CSS) and the Motor Behavioral Assessment (MBA) and specific neurophysiologic and neuroimaging studies in selected participants.
Not Provided
Complete list of historical versions of study NCT00299312 on ClinicalTrials.gov Archive Site
Genetic and Physical Characteristics of Rett syndrome [ Time Frame: Through July 31, 2019 ] [ Designated as safety issue: No ]
The principal secondary outcome measures include quality of life assessments of the participants (CHQ) and the principal caregiver (SF-36).
Not Provided
Genetic and Physical Characteristics of Rett Syndrome, MECP2 Duplication disorder, and RTT-related conditions [ Time Frame: July 31, 2019 ] [ Designated as safety issue: No ]
No other pre-specified outcome measures are planned
Not Provided
 
Genetic and Physical Characteristics of Rett Syndrome
Rett Syndrome Natural History: Genetic and Physical Characteristics of Rett Syndrome

Rett Syndrome (RTT) is a genetic brain disorder that occurs almost exclusively in females and is usually caused by a change (mutation) in the gene MECP2. The disorder is characterized by multiple developmental problems, as well as behavioral features, such as repetitive stereotypic hand movements, including hand washing, wringing, and tapping. While there is no cure for RTT, recent advances in the understanding of the disease suggest that the development of new, effective therapies is promising. This study will gather information on the genetic defects that cause RTT, the physical expressions of these defects, and disease progression. In turn, this may direct the development of future treatments. Expanded studies include individuals with MECP2 Duplication disorder, and RTT-related disorders including individuals with MECP2 mutations, but not meeting obligatory criteria for the diagnosis of RTT and individuals with mutations in CDKL5 and FOXG1 some of whom meet criteria for atypical RTT.

RTT is a brain disorder that causes problems with childhood development. It is usually caused by an abnormality (mutation) in the gene MECP2. RTT can cause severe impairments in movement and communication skills, including speech and social interaction. The first signs of RTT include loss of acquired speech and loss of purposeful hand use for activities such as eating or playing. Individuals may also develop abnormal walking, repetitive hand movements, such as clapping or wringing, and abnormal breathing while awake.

Effective treatments for RTT are currently lacking. There is also inadequate information about the link between RTT clinical features and its genetic basis. In order to prepare for future clinical trials that may lead to effective therapies, it is important to collect accurate information about the characteristics of RTT and the pattern of disease progression. This study will gather historical and physical examination data to establish phenotype-genotype correlations. Data on survival and quality of life in females with RTT and males with MECP2 gene mutations will also be evaluated.

MECP2 Duplication disorder affects principally males who have one and rarely more than one additional copy of MECP2 as well as a variable number of other duplicated genes. These males have absent spoken language, shuffling gait, epilepsy, and, in some, frequent upper respiratory infections or sinusitis. Mother of these males are generally normal due to favorable skewing of X-chromosome inactivation, but in some instances may have neurodevelop-mental delays. Effective treatments are lacking. It is critical to develop phenotype-genotype correlations and longitudinal natural history data to assist the conduct of clinical trials.

RTT-related disorders feature a variety of involvements either due to MECP2, CDKL5, and FOXG1 as well as other potential causes of atypical RTT. Phenotype-genotype studies and longitudinal natural history data are essential to the conduct of future clinical trials.

Participants in this observational study will be recruited from the four sites at which the study is being conducted, as well as through the Rare Disease Clinical Research Network and the International Rett Syndrome Association (IRSA). Prior to study entry, potential participants are expected to be tested for a mutation in the MECP2 gene. No treatment will be administered at any time during this study. Study visits will occur every 6 months until the child is 6 years old and once a year thereafter. At each study visit, participants will be examined to assess physical characteristics of the disorder, such as motor behavior and disease severity. Additionally, participants will complete questionnaires about medical history, contact information, and quality of life. The first visit will last approximately 1.5 hours, and every subsequent visit will last approximately 1 hour.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Individuals fulfilling consensus clinical criteria for Classic or Variant Rett Syndrome, individuals with MECP2 mutations who do not meet the clinical criteria, or individuals who have a duplication of Xq28 including the MECP2 locus or individuals who have mutations in CDKL5 or FOXG1.

Rett Syndrome, MECP2 Duplication dIsorder, and RTT-related Conditions
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1350
July 2019
July 2019   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Meets clinical criteria for classic or variant RTT or tests positive for an MECP2 gene mutation or a MECP2 duplication or a mutation in CDKL5 or FOXG1.

Exclusion Criteria:

  • Unwilling or unable to travel to study sites for annual or biannual evaluations
Both
Not Provided
No
Contact: Alan K Percy, MD 205-996-4927 apercy@uab.edu
Contact: Jane B Lane, RN, BSN 205-934-1130 jlane@uab.edu
United States
 
NCT00299312
RDCRN 5201, U54HD061222, ARP 5201
Yes
Alan Percy, University of Alabama at Birmingham
Alan Percy
  • Rare Diseases Clinical Research Network
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • University of Alabama at Birmingham
  • Greenwood Genetic Center
  • Baylor College of Medicine
  • Children's Hospital Boston
  • University of Rochester
  • Children's Hospital of Philadelphia
  • University of Colorado, Denver
  • Rush University Medical Center
  • Children's Hospital & Research Center Oakland
  • University of California, San Diego
  • Vanderbilt University
  • University of South Florida
Principal Investigator: Alan K Percy, MD University of Alabama at Birmingham
University of Alabama at Birmingham
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP